gms | German Medical Science

GMS Infectious Diseases

Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG)

ISSN 2195-8831

Calculated parenteral initial therapy of bacterial infections: Bacterial meningitis

Guideline Calculated parenteral initial therapy

Search Medline for

  • corresponding author Pramod M. Shah - Frankfurt am Main, Germany
  • Reinhard Brodt - Med. Klinik II / Infektiologie, Universitätsklinikum Frankfurt am Main, Germany
  • Thomas A. Wichelhaus
  • Roland Nau - Geriatrisches Zentrum, Evangelisches Krankenhaus Göttingen-Weende, Göttingen, Germany

GMS Infect Dis 2020;8:Doc07

doi: 10.3205/id000051, urn:nbn:de:0183-id0000519

This is the English version of the article.
The German version can be found at: http://www.egms.de/de/journals/id/2020-8/id000051.shtml

Published: March 26, 2020

© 2020 Shah et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Abstract

This is the thirteenth chapter of the guideline “Calculated initial parenteral treatment of bacterial infections in adults – update 2018” in the 2nd updated version. The German guideline by the Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG) has been translated to address an international audience.

Bacterial meningitis is a life-threatening infectious disease with high mortality and disability rates requiring prompt initiation of antimicrobial treatment to lower these rates.


Introduction

Acute bacterial meningitis is characterized by the clinical cardinal symptoms of fever, headaches and irritation of the meninges (meningism). In addition, confusion, epilepsies or coma may also feature in the clinical presentation [1], [2]. Acute bacterial meningitis must be distinguished from viral meningitis. The most common causes of acute bacterial meningitis acquired outside of hospitals are meningococci and pneumococci. Less common are Haemophilus influenzae, Listeria and Mycobacterium tuberculosis. According to the Infectious Disease Yearbook of Notifiable Diseases 2014, 275 cases of meningococcal meningitis were reported in Germany (incidence 0.3 per 100,000) [3]. Of these, 71.3% belonged to serogroup B, 17.1% to serogroup C, 7.5% to serogroup Y and 4.2% to serogroup W. Data from Germany on the incidence of meningitis caused by pneumococci or listeria are not available. Austria reported an incidence of 0.42/100,000 for pneumococci in 2013 and an incidence of 0.71/100,000 for meningococci (http://www.ages.at/). The pathogen spectrum is age-dependent. Under certain circumstances (post-operative, CSF-associated and immunosuppressed patients), other pathogens such as staphylococci, enterobacteria and pseudomonads can also cause bacterial meningitis.

Meningitis associated with craniofacial infections is mainly caused by pneumococci and other streptococci. There may also be organic manifestations in the CNS in the context of other septic infectious diseases, especially in leptospirosis or Borrelia burgdorferi infections. Subacute or chronic meningitic syndrome is caused in particular by mycobacteria, Candida species, Cryptococcus neoformans, Coccidioides immitis and Treponema pallidum. An atypical progression of meningitis can be expected under severe immunosuppression.


Diagnostics

For all patients blood cultures should be taken. Depending on the location of concomitant infections, it may be necessary to obtain a throat swab, bronchial secretions, urine or a wound swab.

A diagnosis of bacterial meningitis can be proven through lumbar puncture and examination of the cerebrospinal fluid. Granulocytic pleocytosis in excess of 1,000 cells/µl, CSF protein above 100 mg/dl, CSF lactate greater than 3.5 mmol/l and a CSF/serum glucose ratio below 0.3 is typical. Methylene blue staining and Gram staining of the CSF sediment may provide general clues (Gram-negative rods or cocci, Gram-positive rods or cocci). For additional diagnostics, antigen detection methods from the CSF and urine, PCR from the CSF (especially in cases of suspected tuberculous meningitis or for the detection/exclusion of viral CNS infections), CRP/PCT measurement in serum and differential blood counts have proven useful [4]. In subacute meningitis and encephalitis, in particular in neuroborreliosis, the detection of pathogen-specific antibody synthesis in the CNS through determining the CSF/serum antibody index is of great importance [5].

Patients with severe disturbed consciousness, patients with a focal neurological deficit (for example hemiparesis), patients with epileptic seizures within the last few days or immunosuppressed patients who are strongly suspected of having bacterial meningitis should be referred to initial treatment with parenteral antibiotics and dexamethasone immediately after taking the blood sample (for blood culture). Subsequently, a cranial CT and, if the CT findings do not indicate otherwise, a lumbar puncture will be performed [6]. A Swedish study indicates that even in patients with disturbed consciousness CSF can be taken without prior cerebral imaging to determine the etiology. Reducing the time gap between admittance and first dose of antibiotics this way seems to more than outweigh the risk of herniation due to CSF removal [7].


Treatment

Delayed initiation of antibiotic treatment is associated with an unfavorable prognosis [8], [9]. Based on the pathogen spectrum of community-acquired bacterial meningitis, calculated initial treatment (Table 1 [Tab. 1]) with a Group 3a cephalosporin in combination with ampicillin (effect on Listeria) should be initiated [10]. For nosocomial bacterial meningitis and infected CSF drainage, initial treatment consists of vancomycin plus meropenem or vancomycin plus ceftazidime. If a pathogen can be detected, further treatment will be based on the results of the microbiological testing (Table 2 [Tab. 2]). Infected CSF drainage must usually be removed and replaced with external CSF drainage. The duration of treatment with unknown pathogens and meningitis caused by Haemophilus influenzae or Streptococcus pneumoniae should not be less than 10 days and in meningococcal meningitis not less than 7 days. In patients with meningitis caused by Listeria, Staphylococcus aureus, Pseudomonas aeruginosa or enterobacteria, antibiotic treatment lasts 3 weeks.

Fever or an increase in pleocytosis in sterile CSF alone is no reason for prolonging treatment. A final puncture on or after the end of the treatment is not required in cases of uncomplicated progression.

In pathogens with reduced sensitivity to antibiotics, intraventricular antibiotic treatment may be necessary to eliminate the CNS pathogens. At present, no drug is approved for intraventricular administration in Germany and randomized trials which could lead to an improvement of the treatment outcome through intraventricular treatment do not exist. Intraventricular administration of antibiotics thus constitutes an attempted cure. Antibiotics for which intraventricular use makes sense due to low crossover into the CSF even in cases of highly inflammatory meninges and high systemic toxicity and for which experience reports have been published are listed in Table 3 [Tab. 3] [11]. Managing intrathecal treatment by measuring CSF concentrations would appear to be sensible [12].

In a Cochrane analysis of 25 studies on the use of corticosteroids in bacterial meningitis, there was a significant reduction in mortality in countries with high medical standards (diagnosis and treatment) when pneumococci were the causative pathogens (RR 0.84, 95% CI 0,72– 0,98) but not in Haemophilus influenzae or Neisseria meningitidis meningitis [13]. Treatment with corticosteroids also resulted in a significant reduction of damage to hearing (RR 0.74, 95% CI 0.63–0.8) and neurological consequential damage (RR 0.83, 95% CI 0.69–1.00).

Dexamethasone 10 mg i.v. 4 times a day over 4 days plus empirical antibiotic administration is the recommended initial treatment regimen for adult patients suspected of having bacterial meningitis.

Insufficient data are available for patients with nosocomial meningitis and immunosuppressed patients with bacterial meningitis, so adjuvant dexamethasone administration is not recommended. For further adjuvant strategies which have been proven effective in animal experiments, there is insufficient experience in human adults [14], [15]. Due to published negative studies, routine adjuvant therapy with paracetamol, glycerol or hypothermia in bacterial meningitis is not recommended [16], [17], [18].

In tuberculous meningitis, adjuvant administration of dexamethasone or prednisolone improves outcomes [19]. According to a common formula, adults and adolescents in stages II and III receive dexamethasone intravenously 0.4 mg/kg/day in week 1, 0.3 mg/kg/day in week 2, 0.2 mg/kg/day in week 3 and 0.1 mg/kg/day in week 4, followed by oral dexamethasone for 4 weeks with a daily dose reduction of 1 mg per week. In stage I, intravenous administration of dexamethasone 0.3 mg/kg/day in week 1, 0.2 mg/kg/day in week 2, followed by dexamethasone 0.1 mg/kg/day orally in week 3, 3 mg/day orally in week 4, 2 mg/day orally in week 5 and 1 mg/day in week 6 [20]. Alternatively, a prednisolone regimen may be considered, starting at 60–80 mg/day decreasing for 4–6 weeks. Dosage recommendations for tuberculous meningitis see Table 4 [Tab. 4].

For thrombosis prophylaxis, low-dose heparinization and for gastric protection, the application of proton pump inhibitors is recommended.


Prophylaxis

The most common cause of meningitis after splenectomy is Streptococcus pneumoniae, followed by other encapsulated bacterial species. It is therefore recommended that active vaccination using a pneumococcal, hib- and meningococcal vaccine is carried out prior to removal of the spleen (in emergencies also after surgery). Concerning the further indications for Haemophilus-, pneumococcal and meningococcal vaccination, refer to the homepage of the Standing Vaccination Commission of the Robert Koch-Institute (http://www.rki.de/nn_199596/DE/Content/Infekt/Impfen/impfen.html).

Based on current resistance data, people in close contact with patients with meningococcal meningitis acquired in Germany receive antimicrobial prophylaxis up to 10 days after the last patient contact using ciprofloxacin, rifampicin or ceftriaxone [21]. Adults (except pregnant women) receive ciprofloxacin (single dose 500–750 mg p.o.) or alternatively rifampicin (600 mg every 12 hours for 2 days). Pregnant women receive ceftriaxone (single dose 250 mg, i.m.). Children receive rifampicin (10 mg/kg bodyweight every 12 hours for 2 days, p.o.). There have been reports of rifampicin (including as prophylaxis) leading to rapid development of resistance [22]. An increase in ciprofloxacin resistance is to be expected in Neisseria meningitidis strains from southern and western Europe as well as from southeast Asia [23], [24], [25].

People in close contact with patients with Haemophilus influenzae meningitis receive antimicrobial prophylaxis up to 10 days after the last patient contact [26]: Adults (except pregnant women) receive rifampicin (600 mg every 24 hours for 4 days, p.o.); children under the age of 12 receive rifampicin (20 mg/kg body weight every 24 hours for 4 days, p.o.).


Note

This is the thirteenth chapter of the guideline “Calculated initial parenteral treatment of bacterial infections in adults – update 2018” in the 2nd updated version. The German guideline by the Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG) has been translated to address an international audience.


Competing interests

The authors declare that they have no competing interests.


References

1.
Bohr V, Hansen B, Jessen O, Johnsen N, Kjersem H, Kristensen HS, Nyboe J, Rasmussen N. Eight hundred and seventy-five cases of bacterial meningitis. Part I of a three-part series: clinical data, prognosis, and the role of specialised hospital departments. J Infect. 1983 Jul;7(1):21-30. DOI: 10.1016/S0163-4453(83)90894-0 External link
2.
Durand ML, Calderwood SB, Weber DJ, Miller SI, Southwick FS, Caviness VS Jr, Swartz MN. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med. 1993 Jan;328(1):21-8. DOI: 10.1056/NEJM199301073280104 External link
3.
Robert Koch Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2014. Berlin: RKI; 2015. DOI: 10.25646/3224 External link
4.
Marcos MA, Martínez E, Almela M, Mensa J, Jiménez de Anta MT. New rapid antigen test for diagnosis of pneumococcal meningitis. Lancet. 2001 May 12;357(9267):1499-500. DOI: 10.1016/S0140-6736(00)04658-4 External link
5.
Reiber H, Lange P. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin Chem. 1991 Jul;37(7):1153-60.
6.
Deutsche Gesellschaft für Neurologie. Ambulant erworbene bakterielle (eitrige) Meningoenzephalitis im Erwachsenenalter. S2k-Leitlinie. AWMF-Registernummer: 030/089. AWMF; 2015. (Leitlinien für Diagnostik und Therapie in der Neurologie). Available from: https://www.awmf.org/uploads/tx_szleitlinien/030-089l_S2k_Ambulant_erworbene_Meningoenzephalitis_2016-08-verlaengert_01.pdf External link
7.
Glimåker M, Johansson B, Grindborg Ö, Bottai M, Lindquist L, Sjölin J. Adult bacterial meningitis: earlier treatment and improved outcome following guideline revision promoting prompt lumbar puncture. Clin Infect Dis. 2015 Apr;60(8):1162-9. DOI: 10.1093/cid/civ011 External link
8.
Aronin SI, Peduzzi P, Quagliarello VJ. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med. 1998 Dec;129(11):862-9. DOI: 10.7326/0003-4819-129-11_Part_1-199812010-00004 External link
9.
Auburtin M, Wolff M, Charpentier J, Varon E, Le Tulzo Y, Girault C, Mohammedi I, Renard B, Mourvillier B, Bruneel F, Ricard JD, Timsit JF. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit Care Med. 2006 Nov;34(11):2758-65. DOI: 10.1097/01.CCM.0000239434.26669.65 External link
10.
Peltola H, Anttila M, Renkonen OV. Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Finnish Study Group. Lancet. 1989 Jun 10;1(8650):1281-7. DOI: 10.1016/S0140-6736(89)92685-8 External link
11.
Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010 Oct;23(4):858-83. DOI: 10.1128/CMR.00007-10 External link
12.
Ziai WC, Lewin JJ 3rd. Improving the role of intraventricular antimicrobial agents in the management of meningitis. Curr Opin Neurol. 2009 Jun;22(3):277-82. DOI: 10.1097/WCO.0b013e32832c1396 External link
13.
Brouwer MC, van de Beek D. Earlier Treatment and Improved Outcome in Adult Bacterial Meningitis Following Guideline Revision Promoting Prompt Lumbar Puncture. Clin Infect Dis. 2015 Aug;61(4):664-5. DOI: 10.1093/cid/civ328 External link
14.
Nau R, Brück W. Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci. 2002 Jan;25(1):38-45. DOI: 10.1016/S0166-2236(00)02024-5 External link
15.
Nau R, Djukic M, Spreer A, Ribes S, Eiffert H. Bacterial meningitis: an update of new treatment options. Expert Rev Anti Infect Ther. 2015;13(11):1401-23. DOI: 10.1586/14787210.2015.1077700 External link
16.
Ajdukiewicz KM, Cartwright KE, Scarborough M, Mwambene JB, Goodson P, Molyneux ME, Zijlstra EE, French N, Whitty CJ, Lalloo DG. Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. Lancet Infect Dis. 2011 Apr;11(4):293-300. DOI: 10.1016/S1473-3099(10)70317-0 External link
17.
Molyneux EM, Kawaza K, Phiri A, Chimalizeni Y, Mankhambo L, Schwalbe E, Kataja M, Pensulo P, Chilton L, Peltola H. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatr Infect Dis J. 2014 Feb;33(2):214-6. DOI: 10.1097/INF.0000000000000122 External link
18.
Mourvillier B, Tubach F, van de Beek D, Garot D, Pichon N, Georges H, Lefevre LM, Bollaert PE, Boulain T, Luis D, Cariou A, Girardie P, Chelha R, Megarbane B, Delahaye A, Chalumeau-Lemoine L, Legriel S, Beuret P, Brivet F, Bruel C, Camou F, Chatellier D, Chillet P, Clair B, Constantin JM, Duguet A, Galliot R, Bayle F, Hyvernat H, Ouchenir K, Plantefeve G, Quenot JP, Richecoeur J, Schwebel C, Sirodot M, Esposito-Farèse M, Le Tulzo Y, Wolff M. Induced hypothermia in severe bacterial meningitis: a randomized clinical trial. JAMA. 2013 Nov;310(20):2174-83. DOI: 10.1001/jama.2013.280506 External link
19.
Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD002244. DOI: 10.1002/14651858.CD002244.pub3 External link
20.
Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH, Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Nguyen HD, Vu NT, Cao HH, Tran TH, Pham PM, Nguyen TD, Stepniewska K, White NJ, Tran TH, Farrar JJ. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004 Oct;351(17):1741-51. DOI: 10.1056/NEJMoa040573 External link
21.
Nationales Referenzzentrum für Meningokokken und Haemophilus influenza am Institut für Hygiene und Mikrobiologie der Universität Würzburg. Daten zur Laborüberwachung von Meningokokken, 2014. Version 0.2. NRZMHi; 2015. Available from: http://www.meningococcus.uni-wuerzburg.de/startseite/berichte/berichte-meningokokken/daten-2014/ External link
22.
Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004785. DOI: 10.1002/14651858.CD004785.pub3 External link
23.
Alcalá B, Salcedo C, de la Fuente L, Arreaza L, Uría MJ, Abad R, Enríquez R, Vázquez JA, Motgé M, de Batlle J. Neisseria meningitidis showing decreased susceptibility to ciprofloxacin: first report in Spain. J Antimicrob Chemother. 2004 Feb;53(2):409. DOI: 10.1093/jac/dkh075 External link
24.
Singhal S, Purnapatre KP, Kalia V, Dube S, Nair D, Deb M, Aggarwal P, Gupta S, Upadhyay DJ, Rattan A, Raj VS. Ciprofloxacin-resistant Neisseria meningitidis, Delhi, India. Emerging Infect Dis. 2007 Oct;13(10):1614-6. DOI: 10.3201/eid1310.060820 External link
25.
Skoczynska A, Alonso JM, Taha MK. Ciprofloxacin resistance in Neisseria meningitidis, France. Emerging Infect Dis. 2008 Aug;14(8):1322-3. DOI: 10.3201/eid1408.080040 External link
26.
Robert Koch Institut, editor. Epidemiologisches Bulletin. 2002;30. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2002/Ausgabenlinks/30_02.html?nn=237558 External link
27.
Rupprecht TA, Pfister HW. Clinical experience with linezolid for the treatment of central nervous system infections. Eur J Neurol. 2005 Jul;12(7):536-42. DOI: 10.1111/j.1468-1331.2005.01001.x External link
28.
Sousa D, Llinares P, Meijide H, Gutiérrez JM, Miguez E, Sánchez E, Castelo L, Mena A. Clinical experience with linezolid for the treatment of neurosurgical infections. Rev Esp Quimioter. 2011 Mar;24(1):42-7.
29.
Global Tuberculosis Community Advisory Board. TB online. TB Guidelines. Overview. Available from: http://www.tbonline.info/guidelines/ External link
30.
Schaberg T, Bauer T, Brinkmann F, Diel R, Feiterna-Sperling C, Haas W, Hartmann P, Hauer B, Heyckendorf J, Lange C, Nienhaus A, Otto-Knapp R, Priwitzer M, Richter E, Rumetshofer R, Schenkel K, Schoch OD, Schönfeld N, Stahlmann R. S2k-Leitlinie: Tuberkulose im Erwachsenenalter. Eine Leitlinie zur Diagnostik und Therapie, einschließlich Chemoprävention und -prophylaxe des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose e.V. im Auftrag der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V. [Tuberculosis Guideline for Adults – Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP)]. Pneumologie. 2017 Jun;71(6):325-97. DOI: 10.1055/s-0043-105954 External link
31.
Schaberg T, Bauer T, Castell S, Dalhoff K, Detjen A, Diel R, Greinert U, Hauer B, Lange C, Magdorf K, Loddenkemper R. Empfehlungen zur Therapie, Chemoprevention und Chemoprophylaxe der TB im Erwachsenen- und Kindesalter (DZK und DGP) [Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)]. Pneumologie. 2012 Mar;66(3):133-71. DOI: 10.1055/s-0031-1291619 External link
32.
Caminero JA, editor. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. Paris: International Union Against Tuberculosis and Lung Disease; 2013. Available from: http://www.theunion.org/what-we-do/publications/technical/english/mdr-tbguide_6-19-13_web.pdf External link
33.
World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO/HTM/TB/2013.6. Geneva: WHO; 2013. Available from: http://www.who.int/tb/publications/mdrtb-treatment-guideline/en/ External link
34.
World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva: WHO; 2014. Available from: http://www.who.int/tb/publications/pmdt_companionhandbook/en/ External link
35.
Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM; TBNET. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014 Jul;44(1):23-63. DOI: 10.1183/09031936.00188313 External link